1,592 results on '"Katzenellenbogen, John A."'
Search Results
2. Endothelial ERα promotes glucose tolerance by enhancing endothelial insulin transport to skeletal muscle
3. Targeting the oncogenic transcription factor FOXM1 to improve outcomes in all subtypes of breast cancer
4. [18F]Tosyl fluoride as a versatile [18F]fluoride source for the preparation of 18F-labeled radiopharmaceuticals
5. Somatic estrogen receptor [alpha] mutations that induce dimerization promote receptor activity and breast cancer proliferation
6. Effective combination treatments for breast cancer inhibition by FOXM1 inhibitors with other targeted cancer drugs
7. NB compounds are potent and efficacious FOXM1 inhibitors in high-grade serous ovarian cancer cells
8. FOXM1 regulates glycolysis and energy production in multiple myeloma
9. Diffusion tensor imaging identifies aspects of therapeutic estrogen receptor β ligand-induced remyelination in a mouse model of multiple sclerosis
10. Dual-mechanism estrogen receptor inhibitors
11. Solid phase radiosynthesis of an olaparib derivative using 4-[18F] fluorobenzoic acid and in vivo evaluation in breast and prostate cancer xenograft models for PARP-1 expression
12. Asymmetric Allostery in Estrogen Receptor-α Homodimers Drives Responses to the Ensemble of Estrogens in the Hormonal Milieu
13. Abstract B010: Development of folate receptor alpha targeted FOXM1 inhibitors for ovarian cancer
14. Analogues of ERβ ligand chloroindazole exert immunomodulatory and remyelinating effects in a mouse model of multiple sclerosis.
15. Asymmetric allostery in estrogen receptor-a homodimers drives responses to the ensemble of estrogens in the hormonal milieu.
16. Coordinated activation of c-Src and FOXM1 drives tumor cell proliferation and breast cancer progression
17. Increase in chemokine CXCL1 by ERβ ligand treatment is a key mediator in promoting axon myelination
18. Reprogramming of endothelial gene expression by tamoxifen inhibits angiogenesis and ERα-negative tumor growth
19. ESR1 F404 Mutations and Acquired Resistance to Fulvestrant in ESR1-Mutant Breast Cancer
20. The quest for improving the management of breast cancer by functional imaging: The discovery and development of 16α-[18F]fluoroestradiol (FES), a PET radiotracer for the estrogen receptor, a historical review
21. Structural and Molecular Mechanisms of Cytokine-Mediated Endocrine Resistance in Human Breast Cancer Cells
22. Contrasting activities of estrogen receptor beta isoforms in triple negative breast cancer
23. Association of PET-based estradiol-challenge test for breast cancer progesterone receptors with response to endocrine therapy
24. OR11-01 A New Model for Estrogen Receptor-alpha Antagonist Mechanism of Action
25. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors
26. Multiple functional therapeutic effects of the estrogen receptor β agonist indazole-Cl in a mouse model of multiple sclerosis
27. Preliminary evaluation of a novel 18F-labeled PARP-1 ligand for PET imaging of PARP-1 expression in prostate cancer
28. Discovery of long-chain salicylketoxime derivatives as monoacylglycerol lipase (MAGL) inhibitors
29. A chiral pool approach for asymmetric syntheses of both antipodes of equol and sativan
30. Directed Evolution of Specific Receptor-Ligand Pairs for Use in the Creation of Gene Switches
31. Abstract 3984: NB compound FOXM1 inhibitors have potent anti-cancer activity in high-grade serous ovarian carcinoma
32. Data from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
33. Supplementary Figures 1 - 8, Tables 1 - 3 from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
34. Supplementary Methods from Activating ESR1 Mutations Differentially Affect the Efficacy of ER Antagonists
35. Data from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
36. Supplementary Figures_S1-S6 from Structurally Novel Antiestrogens Elicit Differential Responses from Constitutively Active Mutant Estrogen Receptors in Breast Cancer Cells and Tumors
37. Data from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
38. Supplementary Figure 1 from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
39. Supplementary Figure Legends from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
40. Data from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
41. Supplementary Table 1 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
42. Supplementary Figure 3 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
43. Supplementary Figure 2 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
44. Supplementary Figure 1 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
45. Supplementary Figure 5 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
46. Supplementary Figure 7 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
47. Supplementary Figure 6 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
48. Supplementary Materials and Methods from Cyclin D1 Integrates Estrogen-Mediated DNA Damage Repair Signaling
49. Supplementary Figure 4 from c-Src Modulates Estrogen-Induced Stress and Apoptosis in Estrogen-Deprived Breast Cancer Cells
50. Stringing along the estrogen receptor to engage with DNA
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.